Gene: CDCA7
Official Full Name: cell division cycle associated 7provided by HGNC
Gene Summary: This gene was identified as a c-Myc responsive gene, and behaves as a direct c-Myc target gene. Overexpression of this gene is found to enhance the transformation of lymphoblastoid cells, and it complements a transformation-defective Myc Box II mutant, suggesting its involvement in c-Myc-mediated cell transformation. Two alternatively spliced transcript variants encoding distinct isoforms have been reported. [provided by RefSeq, Jul 2008]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO25334 | CDCA7 Knockout cell line (HeLa) | Human | CDCA7 | 1:3~1:6 | Negative | Online Inquiry |
KO25335 | CDCA7 Knockout cell line (HCT 116) | Human | CDCA7 | 1:2~1:4 | Negative | Online Inquiry |
KO25336 | CDCA7 Knockout cell line (HEK293) | Human | CDCA7 | 1:3~1:6 | Negative | Online Inquiry |
KO25337 | CDCA7 Knockout cell line (A549) | Human | CDCA7 | 1:3~1:4 | Negative | Online Inquiry |
CDCA7 Gene Knockout Cell Lines are specialized biological reagents designed for the targeted study of the cell division cycle-associated protein 7 (CDCA7) gene in various cellular contexts. These cell lines have been engineered to have a complete knockout of the CDCA7 gene, which is essential for understanding its role in cellular proliferation, differentiation, and tumorigenesis. By removing the gene product, researchers can precisely analyze the downstream effects on cell biology, including alterations in gene expression profiles, cell cycle dynamics, and apoptotic processes.
The primary mechanism by which these knockout cell lines operate involves the loss of functional CDCA7 protein, significantly impacting pathways crucial for cell cycle regulation. CDCA7 is implicated in cellular responses to stress and is often associated with oncogenic processes. By using these knockout lines, scientists can create models that clarify the gene's contribution to cancer development and progression, thereby opening avenues for targeted therapies.
In the realm of research and clinical applications, CDCA7 Gene Knockout Cell Lines hold significant value. They provide insights into the molecular underpinnings of various cancers, allowing for the identification of potential biomarkers and therapeutic targets. Their utility extends to drug screening assays, where the responsiveness of cancer therapies can be evaluated in a controlled genetic context, thereby improving the predictability of treatment outcomes.
What sets these knockout cell lines apart from alternatives is their rigorously validated genetic modification, ensuring high specificity and reproducibility across experiments. Additionally, they come with comprehensive documentation detailing characterization and performance metrics, facilitating their integration into existing workflows with ease.
For researchers and clinicians focused on cancer biology, the CDCA7 Gene Knockout Cell Lines offer a robust platform for elucidating the complexities of cell signaling pathways and developing innovative therapeutic strategies. Our expertise in genetic engineering and extensive catalog of biological products positions us as a reliable partner in advancing your research objectives while ensuring the highest standards of quality and performance.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.